Scholar Rock (NASDAQ:SRRK) Holdings, Inc. is a clinical-stage biopharmaceutical company leveraging its proprietary Protein Expression Control (PEC) platform to discover and develop innovative therapies that modulate key growth factors. By targeting critical nodes in the transforming growth factor-beta (TGF-β) superfamily, Scholar Rock aims to restore functional muscle growth, enhance tissue repair and overcome immune suppression in various diseases with high unmet medical needs.
The company’s lead therapeutic candidate, apitegromab (SRK-015), is an investigational monoclonal antibody designed to inhibit the activation of myostatin, a negative regulator of muscle mass. Apitegromab is being evaluated in spinal muscular atrophy (SMA) patients to improve motor function and muscle strength across multiple age groups and disease severities. In parallel, Scholar Rock is advancing SRK-181, a highly selective activin A inhibitor, which is under investigation for its potential to augment immune checkpoint inhibitors in pancreatic ductal adenocarcinoma and other solid tumors where immune evasion is driven by activin A signaling. Additional pipeline programs are exploring modulation of growth factors in fibrotic, neuromuscular and oncology indications.
Founded in 2010 and headquartered in Cambridge, Massachusetts, Scholar Rock has built a team of scientists, clinicians and industry veterans dedicated to translating its mechanistic insights into differentiated therapies. The company conducts its clinical trials across North America and Europe, collaborating with leading academic centers and clinical research organizations to advance its candidates through early- and late-stage studies. Strategic partnerships and collaborations have been established to enhance development capabilities and broaden global access to potential future therapies.
Under the leadership of President and Chief Executive Officer Jason Rhodes, Scholar Rock continues to refine its PEC platform and expand its pipeline. Guided by a board comprised of accomplished biopharma executives and scientific advisors, the company remains focused on delivering first-in-class or best-in-class therapeutics. With a commitment to addressing severe and underserved conditions, Scholar Rock combines deep biology expertise with disciplined clinical development to bring novel growth factor modulators to patients worldwide.
